The introduction of Ozempic and Wegovy in Kenya is drawing attention to the country’s growing cardio-metabolic health burden, as healthcare experts call for a more comprehensive approach to the prevention and management of type 2 diabetes, obesity and related conditions. The growing burden of diabetes, obesity and other cardio-metabolic conditions in Kenya is putting renewed focus on the need for early diagnosis, appropriate treatment and long-term disease management. Speaking during a scientific launch event in Nairobi on Saturday to introduce Ozempic for the management of type 2 diabetes and Wegovy for weight management in people living with obesity or overweight with associated health conditions, healthcare experts called for a more comprehensive approach to the prevention and management of type 2 diabetes, obesity and related conditions. Hosted by Novo Nordisk the launch brings renewed attention to two interconnected health challenges that are increasingly placing pressure on individuals, families and health systems, while highlighting the importance of early diagnosis, appropriate treatment, prevention and long-term management. The event brought together healthcare professionals, experts, policymakers and other stakeholders to discuss developments in diabetes and obesity care, the science underpinning new treatment options, and the role of partnerships and innovation in re...
This page contains an attributed headline and the preview text supplied through the publisher’s RSS feed. Copyright in the original reporting belongs to KBC.
